Trevi Therapeutics, Inc.
TRVI Nasdaq
SEC CIK 1563880
Follow Trevi Therapeutics
Weekly email: filings, results
Net income
−$21.5M
−81.8% vs same quarter last year
EPS, diluted
−$0.13
−62.5% vs same quarter last year
Operating cash flow
−$19.7M
−80.9% vs same quarter last year
Operating income
−$24.5M
−76% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$42.8M |
| FY24 | −$47.9M |
| FY23 | −$29.1M |
| FY22 | −$29.2M |
| FY21 | −$33.9M |
| FY20 | −$32.8M |
| FY19 | −$26.1M |
| FY18 | −$20.5M |
| FY17 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$42.1M |
| FY24 | −$38.3M |
| FY23 | −$31.8M |
| FY22 | −$28.3M |
| FY21 | - |
| FY20 | −$29M |
| FY19 | −$23.1M |
| FY18 | −$18.4M |
| FY17 | - |